NCT02930317 - Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions

Hemophilia A

Interventions

DRUG

Recombinant Factor VIII (50 IU/kg)

DRUG

Recombinant Factor VIII (On-demand treatment)

Trial Locations (4)

NOT_YET_RECRUITING

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Anhui provincial hospital, Hefei

RECRUITING

Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology), Tianjin

NOT_YET_RECRUITING

Second hospital of Shanxi Medical University, Taiyuan